BioCentury
ARTICLE | Clinical News

Pfizer hopes new data lead to Ibrance's full first-line approval

April 20, 2016 1:00 AM UTC

Pfizer Inc. (NYSE:PFE) said Ibrance palbociclib plus letrozole met the primary progression-free survival (PFS) endpoint in the Phase III PALOMA-2 study vs. letrozole alone as first-line therapy to treat estrogen receptor-positive, HER2-negative, advanced or metastatic breast cancer in postmenopausal women.

Ibrance has accelerated approval from FDA in combination with letrozole in the first-line setting. Pfizer plans to submit the PALOMA-2 data to FDA along with a request for full approval. ...